Comparison · NCT00399893-2e096ea5
Octreotide vs Placebo Comparator: Number of Participants With Improved Leptin Regulation From Baseline to 6 Months
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Octreotide vs Placebo Comparator: Number of Participants With Improved Leptin Regulation From Baseline to 6 Months. Trial comparisons, record NCT00399893-2e096ea5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00399893-2e096ea5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.0945 | 0.905 | wilson | |
| Risk in group 2 | 0.667 | 0.208 | 0.939 | wilson | |
| Risk difference, group 1 minus group 2 | -0.167 | -0.655 | 0.446 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.151 | 3.72 | log | |
| Odds ratio, group 1 over group 2 | 0.5 | 0.0128 | 19.6 | log | |
| Number needed to treat, for one fewer participant with the outcome on Octreotide than on Placebo Comparator | 6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Octreotide | Octreotide :~Octreotide : Octreotide or placebo to be administered by subcutaneous injection three times daily | 1 | 2 | OG000 |
| Group 2 | Placebo Comparator | Placebo to be administered by subcutaneous injection three times daily while on study | 2 | 3 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Improved Leptin Regulation From Baseline to 6 Months
- Description
- Number of participants with improved Leptin regulation from baseline to 6 months of Octreotide or Placebo therapy
- Time frame
- 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
- NCT number
- NCT00399893
- Phases
- NA
- Conditions
- Prader-Willi Syndrome
- Interventions
- Octreotide, Placebo
- Lead sponsor
- Duke University
- Results first posted
- 2014-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00399893?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00399893-2e096ea5